Glycogen storage cardiomyopathy (PRKAG2): diagnostic findings of standard and advanced echocardiography techniques

被引:15
|
作者
Barros Pena, Jose Luiz [1 ,2 ]
Santos, Wander Costa [1 ]
Albernaz Siqueira, Maria Helena [1 ]
Sampaio, Isaac Hermes [2 ]
Gomes Moura, Isabel Cristina [1 ]
Sternick, Eduardo Back [1 ]
机构
[1] Post Grad Dept Ciencias Med Minas Gerais, Alameda Ezequiel Dias 275, BR-27530130 Belo Horizonte, MG, Brazil
[2] Hosp Felicio Rocho, Echocardiog Dept, Av Contorno 9530, BR-30110934 Belo Horizonte, MG, Brazil
关键词
PRKAG2; cardiomyopathy; speckle tracking echocardiography; left ventricle hypertrophy; 4D strain; HYPERTROPHIC CARDIOMYOPATHY; EUROPEAN ASSOCIATION; AMERICAN SOCIETY; LONGITUDINAL STRAIN; RECOMMENDATIONS; MUTATIONS; UPDATE;
D O I
10.1093/ehjci/jeaa176
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Describe the findings obtained using standard echocardiography (Echo) and deformation indices (2D and 3D speckle tracking strain) in patients (Pts) with PRKAG2 cardiomyopathy. Seek to identify any peculiar characteristics and possible strain patterns that may distinguish this condition from other causes of left ventricular hypertrophy (LVH). Methods and results Thirty Pts with genetically proven PRKAG2 (R302Q and H401Q), 16 (53.3%) male, mean age 39.1 +/- 15.4 years old, were examined using standard, speckle tracking (STE), and 3D Echo. Pacemaker (PM) had been implanted in 12 (40%) Pts with a mean age of 38.1 +/- 13 years. Hypertrophy was found in varying degrees in 18 (86%) Pts. Seven Pts (24%) presented 3D ejection fraction (EF) below normal limits. Diastolic function was abnormal in 17 (63%) Pts. Global longitudinal strain (GLS) on 2D measured -16.4% +/- 5.3%. GLS measured -13.2% +/- 4.8%, global radial strain 40.8% +/- 13.8%, global circumferential strain (GCS) -16.1% +/- 4.4%, and global area strain -26.1% +/- 6.7% by 3D Echo offline analyses. Pts with PM presented lower EF and GCS compared with those without PM. EF/GLS measured 3.65 +/- 1.00. In the bull's eye map, a strain pattern similar to stripes in 18 (60%) Pts was identified, which might be a differentiating signal among LVH. Conclusion Echocardiography is a valuable tool in detecting diffuse and focal myocardial abnormalities in PRKAG2 cardiomyopathy. The deformation indices are especially revealing because they may help distinguish this rare infiltrative disease, thereby favouring early diagnosis, enhanced treatment, and improved outcome.
引用
收藏
页码:800 / 807
页数:8
相关论文
共 50 条
  • [31] Transgenic Overexpression of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) in Mice Mimics PRKAG2 Cardiomyopathy, Whereas Transgenic Knockdown of Cardiac SGLT1 Attenuates PRKAG2 Cardiomyopathy
    Ramratnam, Mohun
    Huang, Xue Yin N.
    Sharma, Ravi
    Lee, So Jung
    D'Auria, Stephen
    Wang, David
    Ahmad, Ferhaan
    CIRCULATION, 2012, 126 (21)
  • [32] Infantile Onset Hypertrophic Cardiomyopathy Secondary to PRKAG2 Gene mutation is Associated with Poor Prognosis
    Gorla, Sudheer R.
    Raja, Kishore R.
    Garg, Ashish
    Barbouth, Deborah S.
    Rusconi, Paolo G.
    JOURNAL OF PEDIATRIC GENETICS, 2018, 7 (04) : 180 - 184
  • [33] Glycogen Storage Disease Because of a PRKAG2 Mutation Causing Severe Biventricular Hypertrophy and High-Grade Atrio-Ventricular Block
    Yogasundaram, Haran
    Paterson, Ian D.
    Graham, Michelle
    Sergi, Consolato
    Oudit, Gavin Y.
    CIRCULATION-HEART FAILURE, 2016, 9 (08)
  • [34] INDUCED PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES FROM A PATIENT CARRYING AN UNPRECEDENTED VARIANT IN THE PRKAG2 GENE SHOW GLYCOGEN STORAGE AND ARE PROMISING TOOLS FOR THE IN VITRO STUDY OF THE METABOLIC CARDIOMYOPATHY
    Bezerra, I. P. S.
    Barbosa, R. A. Q.
    Tocci, J. E.
    Sternick, E. B.
    Kasai-Brunswick, T. H.
    Campos-de-Carvalho, A. C.
    CYTOTHERAPY, 2022, 24 (10) : S9 - S10
  • [35] DEVELOPMENT OF AN IN VITRO STUDY MODEL OF PRKAG2 CARDIOMYOPATHY USING HUMAN INDUCED PLURIPOTENT STEM CELLS
    Bezerra, I. P. S.
    Siqueira, M. E. R. S.
    Barbosa, R. A. Q.
    Sternick, E. B.
    Kasai-Brunswick, T. H.
    Campos-de-Carvalho, A. C.
    CYTOTHERAPY, 2021, 23 (04) : 9 - 10
  • [36] Hypertrophic cardiomyopathy phenocopy (PRKAG2 syndrome) due to p.Arg302Gln mutation
    Rodriguez Ortuno, Julia
    Pena Pena, Maria Luisa
    Lopez Haldon, Jose Eduardo
    MEDICINA CLINICA, 2022, 158 (07): : 340 - 341
  • [37] Transgenic mice overexpressing mutant PRKAG2 recapitulate the human cardiomyopathy, characterized by ventricular hypertrophy and preexcitation
    Arad, M
    Moskowitz, IP
    Patel, VV
    Ahmed, F
    Perez-Atayde, AR
    Sawyer, DB
    Li, GH
    Burgon, PG
    Maguire, CT
    Stapleton, D
    Schmitt, JP
    Guo, XX
    Berul, CI
    Seldman, JG
    Seidman, CE
    CIRCULATION, 2002, 106 (19) : 140 - 140
  • [38] A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis
    Laforêt, P
    Richard, P
    Said, MA
    Romero, NB
    Lacene, E
    Leroy, JP
    Baussan, C
    Hogrel, JY
    Lavergne, T
    Wahbi, K
    Hainque, B
    Duboc, D
    NEUROMUSCULAR DISORDERS, 2006, 16 (03) : 178 - 182
  • [39] Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis
    Hinson, J. Travis
    Chopra, Anant
    Lowe, Andre
    Sheng, Calvin C.
    Gupta, Rajat M.
    Kuppusamy, Rajarajan
    O'Sullivan, John
    Rowe, Glenn
    Wakimoto, Hiroko
    Gorham, Joshua
    Burke, Michael A.
    Zhang, Kehan
    Musunuru, Kiran
    Gerszten, Robert E.
    Wu, Sean M.
    Chen, Christopher S.
    Seidman, Jonathan G.
    Seidman, Christine E.
    CELL REPORTS, 2016, 17 (12): : 3292 - 3304
  • [40] SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy
    Banerjee, Sanjay K.
    Wang, David W.
    Alzamora, Rodrigo
    Huang, Xueyin N.
    Pastor-Soler, Nuria M.
    Hallows, Kenneth R.
    McGaffin, Kenneth R.
    Ahmad, Ferhaan
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2010, 49 (04) : 683 - 692